Time to act: Building a pharmaceutical framework fit for rare diseases
Date
Address
Section
Event Description
We are on the verge of a once-in-a-generation opportunity to determine the future of healthcare in Europe.
To seize this decisive moment, MEP Stelios Kympouropoulos is hosting an event in the European Parliament, Brussels, focusing on the upcoming proposals under the Pharmaceutical Strategy, with a particular focus on rare diseases on 8 February 2023, 18:00-20:00 CET.
In addition to keynote presentations from high-level speakers, our exciting line-up of panellists will address:
- The reality of living with rare disease
- The value of newborn screening: An SMA (spinal muscular atrophy) case study
- Key issues related to the revision of the EU pharmaceutical framework
This event will be a prime opportunity for a discussion amongst EU policymakers, academia, civil society and industry to assess key issues in the spirit of collaboration and to examine how the EU Pharmaceutical Strategy can shape European healthcare and innovation.
This initiative is being organised thanks to the support of EFPIA (The European Federation of Pharmaceutical Industries and Associations). MEP Stelios Kympouropoulos would like to extend his thanks to SMA Europe for their endorsement of this session.
Stay tuned for more details and speaker announcements!
*Do not hesitate to reach out to jonathan@acumenpa.com if you have any questions or issues with the registration process. Practical information will be communicated via email before the event. This is an in-person event.
This event can be followed with Greek interpretation.
Jobs
EURACTIV News
- Compromises on the Pharma Package provide balance, say MEPs ahead of ENVI vote [Advocacy Lab Content]
- Bulgaria tries fighting corruption with mobile access to personal health files [Advocacy Lab Content]
- EHDS is not just an agreement; it’s a promise to patients and researchers, says Vandenbroucke [Advocacy Lab Content]
- Reducing regulatory data protection isn’t a successful strategy, says Roche Netherlands GM [Advocacy Lab Content]
- Investigation into Slovak pandemic management tainted by anti-vaxxer leadership [Advocacy Lab Content]